Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23573528 | 0.90 | HTT (0.72) | HTTPOLBKDM4EALDH1A1MAPK1 | |
| SCHEMBL23573223 | 0.82 | HTT (0.61) | HTTPOLBKDM4EALDH1A1MAPK1 | |
| SCHEMBL23573566 | 0.82 | HTT (0.61) | HTTPOLBKDM4EALDH1A1MAPK1 | |
| SCHEMBL23573222 | 0.82 | HTT (0.61) | HTTPOLBKDM4EALDH1A1MAPK1 | |
| SCHEMBL10156627 | 0.82 | HTT (0.55) | HTTPOLBKDM4EALDH1A1MAPK1 | |
| SCHEMBL4560498 | 0.80 | HTT (0.76) | HTTPOLBKDM4EALDH1A1MAPK1 | |
| SCHEMBL5201039 | 0.80 | HTT (0.83) | HTTPOLBKDM4EALDH1A1MAPK1 | |
| SCHEMBL6539120 | 0.79 | EPHX2 (0.65) | EPHX1 | |
| SCHEMBL12859653 | 0.79 | MAPK1 (0.66) | HTTPOLBKDM4EALDH1A1MAPK1 | |
| SCHEMBL23573522 | 0.79 | EPHX1 (0.42) | HTTPOLBALDH1A1PKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2021-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198239-A1 | COMPOUNDS AND METHODS FOR CD73 MODULATION AND INDICATIONS THEREFOR | ENTPD5, ADORA2A, ENTPD1 | HTT 2799/4885POLB 1763/4885KDM4E 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.